Your browser doesn't support javascript.
loading
Androgen receptor inhibitor-induced "BRCAness" and PARP inhibition are synthetically lethal for castration-resistant prostate cancer.
Li, Likun; Karanika, Styliani; Yang, Guang; Wang, Jiangxiang; Park, Sanghee; Broom, Bradley M; Manyam, Ganiraju C; Wu, Wenhui; Luo, Yong; Basourakos, Spyridon; Song, Jian H; Gallick, Gary E; Karantanos, Theodoros; Korentzelos, Dimitrios; Azad, Abul Kalam; Kim, Jeri; Corn, Paul G; Aparicio, Ana M; Logothetis, Christopher J; Troncoso, Patricia; Heffernan, Timothy; Toniatti, Carlo; Lee, Hyun-Sung; Lee, Ju-Seog; Zuo, Xuemei; Chang, Wenjun; Yin, Jianhua; Thompson, Timothy C.
Affiliation
  • Li L; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030-4009, USA.
  • Karanika S; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030-4009, USA.
  • Yang G; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030-4009, USA.
  • Wang J; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030-4009, USA.
  • Park S; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030-4009, USA.
  • Broom BM; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030-4009, USA.
  • Manyam GC; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030-4009, USA.
  • Wu W; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030-4009, USA.
  • Luo Y; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030-4009, USA.
  • Basourakos S; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030-4009, USA.
  • Song JH; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030-4009, USA.
  • Gallick GE; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030-4009, USA.
  • Karantanos T; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030-4009, USA.
  • Korentzelos D; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030-4009, USA.
  • Azad AK; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030-4009, USA.
  • Kim J; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030-4009, USA.
  • Corn PG; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030-4009, USA.
  • Aparicio AM; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030-4009, USA.
  • Logothetis CJ; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030-4009, USA.
  • Troncoso P; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030-4009, USA.
  • Heffernan T; Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, TX 77030-4009, USA.
  • Toniatti C; ORBIT (Oncology Research for Biologics and Immunotherapy Translation), The University of Texas MD Anderson Cancer Center, Houston, TX 77030-4009, USA.
  • Lee HS; Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030-4009, USA.
  • Lee JS; Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030-4009, USA.
  • Zuo X; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030-4009, USA.
  • Chang W; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030-4009, USA.
  • Yin J; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030-4009, USA.
  • Thompson TC; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030-4009, USA. timthomp@mdanderson.org.
Sci Signal ; 10(480)2017 May 23.
Article in En | MEDLINE | ID: mdl-28536297

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Phenylthiohydantoin / Phthalazines / Piperazines / Gene Expression Regulation, Neoplastic / BRCA1 Protein / Prostatic Neoplasms, Castration-Resistant / Poly(ADP-ribose) Polymerase Inhibitors Limits: Animals / Humans / Male Language: En Journal: Sci Signal Journal subject: CIENCIA / FISIOLOGIA Year: 2017 Document type: Article Affiliation country: United States Country of publication: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Phenylthiohydantoin / Phthalazines / Piperazines / Gene Expression Regulation, Neoplastic / BRCA1 Protein / Prostatic Neoplasms, Castration-Resistant / Poly(ADP-ribose) Polymerase Inhibitors Limits: Animals / Humans / Male Language: En Journal: Sci Signal Journal subject: CIENCIA / FISIOLOGIA Year: 2017 Document type: Article Affiliation country: United States Country of publication: United States